Latest Breaking News On - Patient centricity division - Page 1 : comparemela.com

EORTC partners with Pierre Fabre to support patients with stage 2 melanoma European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre today announced a strategic partnership in support of patients with resected Stage 2 BRAF-mutant melanoma. The partnership includes the planning, design and execution of a large Phase 3 study investigating the use of BRAF and MEK targeted therapies to reduce the risk of relapse in this patient population, currently under approval with authorities. Sadly, still today too many patients with Stage 2 melanoma have their cancer come back, even after their tumor is removed. Further understanding how effective treatments can have an impact on recurrence is essential. We are pleased to collaborate with Pierre Fabre who bring strong heritage and expertise in this therapeutic area, to make a true difference to people living with Stage 2 melanoma.

Pierre fabreDenis lacombeDeborah szafirEmily hendersonPatient centricity division at pierre fabreEuropean organisation for researchPatient centricity divisionபியர் ஃபேப்ரேடெனிஸ் லாகோம்பேஎமிலி ஹென்டர்சன்ஐரோப்பிய ஆர்கநைஸேஶந் க்கு ஆராய்ச்சி